1. Valent P (2009): Pathogenesis, classification, and therapy of Eosinophilia and Eosinophil disorders. Blood Rev 23: 157-165.
2.
Gleich GJ (2000): Mechanisms of Eosinophil-associated inflammation. J Allergy Clin Immunol 105: 651-663.
3.
Valent P, Gleich GJ, Reiter A, et al. (2012): Pathogenesis and classification of eosinophil disorders: A review of recent developments in the field. Expert Rev Hematol 5: 157-176.
4.
Falchi L, Verstovsek S (2015): Eosinophilia in hematologic disorders. Immunol Allergy Clin North Am 35: 439-452.
5.
Gotlib J (2014): World Health Organization-defined Eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. Am J Hematol 89: 325-337.
6.
Brigden M, Graydon C (1997): Eosinophilia detected by automated blood cell counting in ambulatory North American outpatients. Incidence and clinical significance. Arch Pathol Lab Med 121: 963-967.
7.
Tefferi A, Patnaik MM, Pardanani A (2006): Eosinophilia: Secondary, clonal and idiopathic. Br J Haematol 133: 468-492.
8.
Valent P, Klion AD, Horny HP, et al. (2012): Contemporary consensus proposal on criteria and classification of Eosinophilic disorders and related syndromes. J Allergy Clin Immunol 130: 607-612.e9.
9.
Gotlib J (2017): World Health Organization-defined Eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol 92: 1243-1259.
10.
Brito-Babapulle F (2003): The Eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol 121: 203-223.
11.
Gotlib J (2011): World Health Organization-defined Eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. Am J Hematol 86: 677-688.
12.
Kay AB (2016): Paul Ehrlich and the early history of granulocytes. Microbiol Spectr 4, doi: 10.1128/microbiolspec.MCHD-0032-2016.
13.
Fulkerson PC, Rothenberg ME (2018): Eosinophil development, disease involvement, and therapeutic suppression. Adv Immunol 138: 1-34.
14.
Mori Y, Iwasaki H, Kohno K, et al. (2009): Identification of the human eosinophil lineage-committed progenitor: Revision of phenotypic definition of the human common myeloid progenitor. J Exp Med 206: 183-193.
15.
Menzies-Gow A, Flood-Page P, Sehmi R, et al. (2003): Anti- IL-5 (Mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 111: 714-719.
16.
Anderson EL, Kobayashi T, Iijima K, et al. (2016): IL-33 mediates reactive Eosinophilopoiesis in response to airborne allergen exposure. Allergy 71: 977-988.
17.
Simon D, Simon HU (2007): Eosinophilic disorders. J Allergy Clin Immunol 119: 1291-1300.
18.
Woolnough K, Wardlaw AJ (2015): Eosinophilia in pulmonary disorders. Immunol Allergy Clin North Am 35: 477-492.
19.
Uribe Echevarría L, Leimgruber C, García González J, et al. (2017): Evidence of eosinophil extracellular trap cell death in COPD: Does it represent the trigger that switches on the disease? Int J Chron Obstruct Pulmon Dis 12: 885-896.
20.
Curtis C, Ogbogu P (2016): Hypereosinophilic syndrome. Clin Rev Allergy Immunol 50: 240-251.
21.
Zimmermann N, Wikenheiser-Brokamp KA (2018): Hypereosinophilic syndrome in the differential diagnosis of pulmonary infiltrates with eosinophilia. Ann Allergy Asthma Immunol 121: 179-185.
22.
Cheung AC, Hachem CY, Lai J (2016): Idiopathic hypereosinophilic syndrome presenting with hepatitis and achalasia. Clin J Gastroenterol 9: 238-242.
23.
Yamada Y, Rothenberg ME, Cancelas JA (2006): Current concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia. Transl Oncogenomics 1: 53-63.
24.
Kahn JE, Groh M, Lefèvre G (2017): (A Critical Appraisal of) Classification of Hypereosinophilic Disorders. Front Med (Lausanne) 4: 216.
25.
Chusid MJ, Dale DC, West BC, Wolff SM (1975): The hypereosinophilic syndrome: Analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54: 1-27.
26.
Klion AD, Law MA, Riemenschneider W, et al. (2004): Familial Eosinophilia: A benign disorder? Blood 103: 4050-4055.
27.
Khoury, P.; Bochner, B.S. Consultation for Elevated Blood Eosinophils: Clinical Presentations, High Value Diagnostic Tests, and Treatment Options. J Allergy Clin Immunol Pract 2018, 6, 1446–1453, doi:10.1016/j.jaip.2018.04.030.
28.
O’Connell EM, Nutman TB (2015): Eosinophilia in infectious diseases. Immunol Allergy Clin North Am 35: 493-522.
29.
Gajadhar AA, Pozio E, Gamble HR, et al. (2009): Trichinella diagnostics and control: Mandatory and best practices for ensuring food safety. Vet Parasitol 159: 197-205.
30.
Sharma RK, Raghavendra N, Mohanty S, et al. (2014): Clinical & biochemical profile of trichinellosis outbreak in North India. Indian J Med Res 140: 414-419.
31.
Hall RL, Lindsay A, Hammond C, et al. (2012): Outbreak of human Trichinellosis in Northern California caused by Trichinella Murrelli. Am J Trop Med Hyg 87: 297-302.
32.
Webb CM, Cabada MM (2018): Recent developments in the epidemiology, diagnosis, and treatment of fasciola infection. Curr Opin Infect Dis 31: 409-414.
33.
de Jesus AR, Silva A, Santana LB, et al. (2002): Clinical and immunologic evaluation of 31 patients with acute schistosomiasis mansoni. J Infect Dis 185: 98-105.
34.
Khan A, Zahoor S, Ahmed H, et al. (2018): A retrospective analysis on the cystic echinococcosis cases occured in Northeastern Punjab province, Pakistan. Korean J Parasitol 56: 385-390.
35.
Fahim F, Al Salamah SM (2007): Cystic Echinococcosis in Central Saudi Arabia: A 5-year experience. Turk J Gastroenterol 18: 22-27.
36.
Lv H, Jiang Y, Liu G, et al. (2015): Surgical treatment of multiple hydatid cysts in the liver of a pediatric patient. Am J Trop Med Hyg 92: 595-598.
37.
Schulte C, Krebs B, Jelinek T, et al. (2002): Diagnostic significance of blood eosinophilia in returning travelers. Clin Infect Dis 34: 407-411.
38.
Allen J, Wert M (2018): Eosinophilic pneumonias. J Allergy Clin Immunol Pract 6: 1455-1461.
39.
Duray PH (1989): Clinical pathologic correlations of Lyme disease. Rev Infect Dis 11 Suppl 6: S1487-1493.
40.
Buda P, Zawadka K, Wadowska-Kłopotek W, et al. (2015): Cerebrospinal fluid eosinophilia in a child with neuroborreliosis. Wiad Lek 68: 92-94.
41.
Granter SR, Barnhill RL, Duray PH (1996): Borrelial fasciitis: Diffuse fasciitis and peripheral eosinophilia associated with borrelia infection. Am J Dermatopathol 18: 465-473.
42.
Garg G, Gogia A, Kakar A, Miglani P (2017): Persistent marked peripheral eosinophilia due to tuberculosis: A case report. Iran J Med Sci 42: 102-105.
43.
Chou A, Serpa JA (2015): Eosinophilia in patients infected with human immunodeficiency virus. Curr HIV/AIDS Rep 12: 313-316.
44.
Newby C, Agbetile J, Hargadon B, et al. (2014): Lung function decline and variable airway inflammatory pattern: Longitudinal analysis of severe asthma. J Allergy Clin Immunol 134: 287-294.
45.
Loutsios C, Farahi N, Porter L, et al. (2014): Biomarkers of eosinophilic inflammation in asthma. Expert Rev Respir Med 8: 143-150.
46.
Pashley CH (2014): Fungal culture and sensitisation in asthma, cystic fibrosis and chronic obstructive pulmonary disorder: What does it tell us? Mycopathologia 178: 457-463.
47.
Ho MHK, Wong WHS, Chang C (2014): Clinical spectrum of food allergies: A comprehensive review. Clin Rev Allergy Immunol 46: 225-240.
48.
Lyons JJ, Milner JD, Stone KD (2015): Atopic dermatitis in children: Clinical features, pathophysiology, and treatment. Immunol Allergy Clin North Am 35: 161-183.
49.
Cuestas D, Forero Y, Galvis I, et al. (2018): Drug reaction with eosinophilia and systemic symptoms (DRESS) and multiple organ dysfunction syndrome (MODS): One more reason for a new effective treatment against leishmaniasis. Int J Dermatol 57: 1304-1313.
50.
Bocquet H, Bagot M, Roujeau JC (1996): Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg 15: 250-257.
51.
Descamps V, Ranger-Rogez S (2014): DRESS syndrome. Joint Bone Spine 81: 15-21.
52.
Pichler WJ, Adam J, Watkins S, et al. (2015): Drug hypersensitivity: How drugs stimulate T cells via pharmacological interaction with immune receptors. Int Arch Allergy Immunol 168: 13-24.
53.
Roujeau JC, Dupin N (2017): Virus reactivation in drug reaction with eosinophilia and systemic symptoms (Dress) results from a strong drug-specific immune response. J Allergy Clin Immunol Pract 5: 811-812.
54.
Tamaki H, Chatterjee S, Langford CA (2015): Eosinophilia in rheumatologic/vascular disorders. Immunol Allergy Clin North Am 35: 453-476.
55.
Jakiela B, Szczeklik W, Plutecka H, et al. (2012): Increased production of IL-5 and dominant Th2-type response in airways of Churg-Strauss syndrome patients. Rheumatology (Oxford) 51: 1887-1893.
56.
Hilhorst M, Maria AT, Kavian N, et al. (2018): Impact of MPO-ANCA-mediated oxidative imbalance on renal vasculitis. Am J Physiol Renal Physiol 315: F1769-F1776.
57.
Khoury P, Zagallo P, Talar-Williams C, et al. (2012): Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome. Allergy 67: 1149-1156.
58.
Legatowicz-Koprowska M (2018): IgG4-related disease: Why is it so important? Cent Eur J Immunol 43: 204-208.
59.
Allen JA, Peterson A, Sufit R, et al. (2011): Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. Arthritis Rheum 63: 3633-3639.
60.
Selva-O’Callaghan A, Trallero-Araguás E, Grau JM (2014): Eosinophilic myositis: An updated review. Autoimmun Rev 13: 375-378.
61.
Brugnoni D, Airó P, Rossi G, et al. (1996): A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5. Blood 87: 1416-1422.
62.
Rigoni A, Colombo MP, Pucillo C (2018): Mast cells, basophils and eosinophils: From allergy to cancer. Semin Immunol 35: 29-34.
63.
Carretero R, Sektioglu IM, Garbi N, et al. (2015): Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol 16: 609-617.
64.
Click B, Anderson AM, Koutroubakis IE, et al. (2017): Peripheral eosinophilia in patients with inflammatory bowel disease defines an aggressive disease phenotype. Am J Gastroenterol 112: 1849-1858.
65.
Imahashi N, Miyamura K, Seto A, et al. (2010): Eosinophilia predicts better overall survival after acute graft-versus-host-disease. Bone Marrow Transplant 45: 371-377.
66.
Charmandari E, Nicolaides NC, Chrousos GP (2014): Adrenal insufficiency. Lancet 383: 2152-2167.
67.
Saffar AS, Ashdown H, Gounni AS (2011): The molecular mechanisms of glucocorticoids-mediated neutrophil survival. Curr Drug Targets 12: 556-562.
68.
Singh AD, Suri TM, Jagdish RK, Kumar U (2018): Unravelling the NERDS syndrome. BMJ Case Rep 2018: bcr2017223506, bcr-2017–223506.
69.
Banerji A, Weller PF, Sheikh J (2006): Cytokine-associated angioedema syndromes including episodic angioedema with eosinophilia (Gleich’s syndrome). Immunol Allergy Clin North Am 26: 769-781.
70.
Zhu S, Wei P, Chen J, et al. (2015): Diagnosis and treatment of a patient with Kimura’s disease associated with nephrotic syndrome and lymphadenopathy of the epitrochlear nodes. BMC Nephrol 16: 10.
71.
Xie DP, Xu YF, Li MQ (2018): Kimura’s disease presenting as scrotal mass: A difficult diagnosis. Urol J 15: 295-296.
72.
Pardanani A, Tefferi A (2008): Primary eosinophilic disorders: A concise review. Curr Hematol Malig Rep 3: 37-43.
73.
Helbig G, Soja A, Bartkowska-Chrobok A, Kyrcz-Krzemień S (2012): Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation. Am J Hematol 87: 643-645.
74.
Arber DA, Orazi A, Hasserjian R, et al. (2016): The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127: 2391-2405.
75.
Bain BJ, Ahmad S (2014): Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities? Br J Haematol 166: 809-817.
76.
Wang L, Pan Q, Fu J, et al. (2008): FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib. Chin Med J (Engl) 121: 867-873.
77.
Gotlib J (2015): Tyrosine kinase inhibitors and therapeutic antibodies in advanced eosinophilic disorders and systemic mastocytosis. Curr Hematol Malig Rep 10: 351-361.
78.
Tefferi A, Gotlib J, Pardanani A (2010): Hypereosinophilic syndrome and clonal eosinophilia: Point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc 85: 158-164.
79.
Lefebvre C, Bletry O, Degoulet P, et al. (1989): Prognostic factors of hypereosinophilic syndrome. Study of 40 cases. Ann Med Interne (Paris) 140: 253-257.
